CureVac (CVAC) said Monday the US Food and Drug Administration has cleared the company to initiate a phase 1 study of its experimental mRNA-based therapy, CVHNLC, in patients with squamous non-small cell lung cancer.
The company said the open-label, dose-finding study will evaluate the safety and tolerability of CVHNLC in combination with pembrolizumab in patients.
The study will include a dose-escalation phase for first-line maintenance treatment following chemotherapy and pembrolizumab or pembrolizumab monotherapy, followed by an optional dose expansion phase combining CVHNLC with first-line chemotherapy and pembrolizumab, the drug developer said.
Shares of the company rose more than 1% in recent premarket activity.
Price: 2.62, Change: +0.03, Percent Change: +1.16
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。